12 Month Price Forecast For GRAL
Distance to GRAL Price Forecasts
GRAL Price Momentum
๐ค Considering GRAIL (GRAL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 8:26 AM UTC
GRAL Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, GRAL has a neutral consensus with a median price target of $14.50 (ranging from $13.00 to $16.00). Currently trading at $33.37, the median forecast implies a -56.5% downside. This outlook is supported by 0 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tejas Savant at Morgan Stanley, projecting a 52.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GRAL Analyst Consensus
GRAL Price Target Range
Latest GRAL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GRAL.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 27, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Initiates | $16.00 |
Oct 17, 2024 | Guggenheim | Subbu Nambi | Neutral | Initiates | $0.00 |
Stocks Similar to GRAIL, Inc.
The following stocks are similar to GRAIL based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GRAIL, Inc. (GRAL) Financial Data
GRAIL, Inc. has a market capitalization of $1.08B with a P/E ratio of -0.8x. The company generates $117.67M in trailing twelve-month revenue with a -102.7% profit margin.
Revenue growth is +38.3% quarter-over-quarter, while maintaining an operating margin of -640.5% and return on equity of -35.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

GRAIL, Inc. (GRAL) Company Overview
About GRAIL, Inc.
Develops technologies for early cancer detection.
The company generates revenue through its innovative screening and diagnostic tests, including Galleri for asymptomatic individuals and DAC as a diagnostic aid. By focusing on early detection, GRAIL aims to improve patient outcomes while also addressing a significant market need for accurate and timely cancer diagnostics.
Founded in 2015 and based in Menlo Park, California, GRAIL, Inc. was previously a subsidiary of Illumina, Inc. The company is actively engaged in developing additional tests for minimal residual disease and other post-diagnostic applications, positioning itself as a leader in early cancer detection technologies.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,360
CEO
Mr. Robert P. Ragusa
Country
United States
IPO Year
2024
Website
grail.comGRAIL, Inc. (GRAL) Latest News & Analysis
Grail (GRAL) shares hit a new record high, reflecting strong gains due to positive sentiment surrounding its early-detection cancer screening blood tests.
Grail's record-high share price reflects strong market confidence in its innovative cancer screening technology, potentially driving future growth and investment interest.
Grail, Inc. (GRAL) shares rose 20% intraday on Wednesday, making it the top gainer in the Nasdaq 100, surpassing Arm Holdings (ARM) and Netflix (NFLX).
Grail, Inc.'s 20% share surge signals strong market interest and potential growth, indicating investor confidence and shifting focus within the Nasdaq 100, impacting overall market dynamics.
GRAIL, Inc. reported minimal patient distress from multi-cancer early detection testing in the PATHFINDER study, with findings published in Lancet Oncology.
Positive patient-reported outcomes from GRAIL's PATHFINDER study could enhance the company's credibility and market potential, influencing its stock performance in the healthcare sector.
GRAIL, Inc. (Nasdaq: GRAL) will present at the 43rd Annual J.P. Morgan Healthcare Conference, focusing on early cancer detection.
GRAIL's presentation at a major conference highlights its potential for breakthroughs in cancer detection, influencing investor confidence and stock performance in the healthcare sector.
GRAIL (NASDAQ: GRAL) shares have increased by 58% since October 24, demonstrating strong performance over the past month and a half.
GRAIL's 58% share price increase indicates strong market momentum, potentially signaling investor confidence and future growth prospects in the biotech sector.
One Of IBD's Best Screens Identifies These Four Market Leaders, Including Garmin, Ollie's
2 months agoGarmin and Ollie's Bargain Outlet are highlighted as top stocks to watch today, according to Investor's Business Daily's market analysis.
Garmin and Ollie's Bargain Outlet are identified as market leaders, indicating potential growth and investment opportunities, which could influence stock performance and investor interest.
Frequently Asked Questions About GRAL Stock
What is GRAIL, Inc.'s (GRAL) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, GRAIL, Inc. (GRAL) has a median price target of $14.50. The highest price target is $16.00 and the lowest is $13.00.
Is GRAL stock a good investment in 2025?
According to current analyst ratings, GRAL has 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $33.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GRAL stock?
Wall Street analysts predict GRAL stock could reach $14.50 in the next 12 months. This represents a -56.5% decrease from the current price of $33.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GRAIL, Inc.'s business model?
The company generates revenue through its innovative screening and diagnostic tests, including Galleri for asymptomatic individuals and DAC as a diagnostic aid. By focusing on early detection, GRAIL aims to improve patient outcomes while also addressing a significant market need for accurate and timely cancer diagnostics.
What is the highest forecasted price for GRAL GRAIL, Inc.?
The highest price target for GRAL is $16.00 from Tejas Savant at Morgan Stanley, which represents a -52.1% decrease from the current price of $33.37.
What is the lowest forecasted price for GRAL GRAIL, Inc.?
The lowest price target for GRAL is $13.00 from at , which represents a -61.0% decrease from the current price of $33.37.
What is the overall GRAL consensus from analysts for GRAIL, Inc.?
The overall analyst consensus for GRAL is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $14.50.
How accurate are GRAL stock price projections?
Stock price projections, including those for GRAIL, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.